Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The FDA’s recent rejection of a rare disease cell therapy — despite prior internal support and an approval in Europe — is prompting questions about whether the agency’s rhetoric matches its regulatory actions under the new leadership.
Also, an independent researcher outlines why clinical trials of supplements are so very flawed, and we delve into a looming epilepsy data readout. Continue to STAT+ to read the full story…